STAT Plus: UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus
Another Massachusetts biotech is being bought by a big foreign drug company.
Belgian-based UCB said Thursday it plans to buy Ra Pharmaceuticals, a Cambridge, Mass., company that is developing treatments for rare diseases, for about $2.5 billion. UCB is paying $48 a share, more than double Ra’s closing price Wednesday.
Continue to STAT Plus to read the full story…
